What age group is Zostavax recommended for?

Zostavax is a vaccine specifically designed to reduce the risk of shingles (herpes zoster) in older adults. The Centers for Disease Control and Prevention (CDC) recommends that Zostavax be administered to individuals who are at least 50 years old. This age group is targeted because the risk of developing shingles and its complications increases significantly with age, particularly among those aged 50 and older.

Those under 50 years are not included in the recommended age group for Zostavax because studies have shown that the vaccine's effectiveness is greatest in older adults, who are more susceptible to shingles. Additionally, there is no recommendation to vaccinate all ages with this particular vaccine, as the primary protective benefit is intended for those in the demographic where shingles is more prevalent. Therefore, the clear guideline is that the appropriate age for receiving Zostavax is at least 50 years old.